The effect of thiazolidinediones on adiponectin serum level: a meta-analysis (Q36889121)

16 August 2017

1 reference

title

The effect of thiazolidinediones on adiponectin serum level: a meta-analysis (English)

1 reference

16 August 2017

1 reference

Riera-Guardia N

1 reference

16 August 2017

Rothenbacher D

series ordinal

1 reference

16 August 2017

publication date

21 July 2007

1 reference

Diabetes, Obesity and Metabolism

16 August 2017

published in

1 reference

16 August 2017

1 reference

16 August 2017

1 reference

16 August 2017

page(s)

367-375

1 reference

Keynote review: the adipocyte as a drug discovery target

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

Adiponectin: more than just another fat cell hormone?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

Systematic review: adipose tissue, obesity and gastrointestinal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

Review article: adipocytokines and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

Statistical methods for assessing the influence of study characteristics on treatment effects in 'meta-epidemiological' research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

Operating characteristics of a rank correlation test for publication bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

Effects of rosglitazone on plasma adiponectin, insulin sensitivity, and insulin secretion in high-risk African Americans with impaired glucose tolerance test and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

Peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist increases plasma adiponectin levels in type 2 diabetic patients with proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

Individual and combined effects of peroxisome proliferator-activated receptor and {gamma} agonists, fenofibrate and rosiglitazone, on biomarkers of lipid and glucose metabolism in healthy nondiabetic volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

Relationship of plasma extracellular-superoxide dismutase level with insulin resistance in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

Adiponectin and protection against type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

Plasma adiponectin levels and risk of myocardial infarction in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

Adiponectin and future coronary heart disease events among men with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00755.X

10.1111/J.1463-1326.2007.00755.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference